LabCorp’s cancer test found effective in Phase II study

Using six biomarkers, this blood test can discriminate between disease-free women and ovarian cancer patients (stage I-IV) with high specificity (99.4%) and sensitivity (95.3%). LabCorp and Yale are hopeful that this test will be available to women by the end of the year.

Myla Lai-Goldman, executive vice president, chief scientific officer and medical director of LabCorp, said: “Being able to detect early stage ovarian cancer will enable physicians to treat this disease early. Survival rates for women with the disease detected early can be as high as 90%, yet, if not diagnosed early, the survival rate drops to only 20%.”